SCHEMBL2770708

SCHEMBL2770708

OCc1ccc2[nH]nc3c2c1C=Cc1ccccc1-3

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK10 P53779 4/20 0.38
MAPK8 P45983 2/20 0.38
MAPK9 P45984 2/20 0.38
MAPK1 P28482 2/20 0.38
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 2/20 0.38
TTK P33981 2/20 0.38
CHEK1 O14757 2/20 0.38
AURKA O14965 2/20 0.38
MEN1 O00255 1/20 0.38
CDC7 O00311 1/20 0.38
PLK4 O00444 1/20 0.38
IKBKB O14920 1/20 0.38
RGS12 O14924 1/20 0.38
GAK O14976 1/20 0.38
NPC1 O15118 1/20 0.38
PDPK1 O15530 1/20 0.38
DAPK3 O43293 1/20 0.38
DYRK3 O43781 1/20 0.38
ROCK2 O75116 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2768184 0.81 MAP2K4 (0.42) MAPK10MAPK8MAPK9MAPK1KDM4E
SCHEMBL2770623 0.75 KDR (0.56) MAPK10MAPK8MAPK9MAPK1KDM4E
SCHEMBL2769231 0.69 MAPK10 (0.49) MAPK10MAPK8MAPK9MAPK1KDM4E
SCHEMBL2768496 0.64 KDR (0.43) MAPK10MAPK8MAPK9MAPK1KDM4E
SCHEMBL2516091 0.63 ALDH1A1 (0.36) ALDH1A1MEN1CYP1A2CYP3A4TSHR
SCHEMBL5971620 0.62 ALDH1A1 (0.56) MAPK10MAPK8MAPK9MAPK1KDM4E
SCHEMBL2768700 0.61 MAPK10 (0.52) MAPK10MAPK8MAPK9MAPK1KDM4E
SCHEMBL14443102 0.60 MAPT (0.56) MAPK10MAPK8MAPK9MAPK1KDM4E
SCHEMBL19414364 0.57 SRC (0.43) MAPK8MAPK9CHEK1DAPK3PRKD3
SCHEMBL170980 0.56 ALDH1A1 (1.00) MAPK10MAPK8MAPK9MAPK1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1479670-B1 NOVEL FUSED RING INDAZOLE COMPOUNDS EISAI R&D MAN CO LTD (JP) 2010-04-21 EP disclosed
EP-1479670-B1 NOVEL FUSED RING INDAZOLE COMPOUNDS EISAI R&D MAN CO LTD (JP) 2010-04-21 EP disclosed
US-7390797-B2 Fused indazole compounds EISAI CO., LTD. (JP) 2008-06-24 US disclosed
US-7390797-B2 Fused indazole compounds EISAI CO., LTD. (JP) 2008-06-24 US disclosed
US-7390797-B2 Fused indazole compounds EISAI CO., LTD. (JP) 2008-06-24 US disclosed
US-20060111419-A1 Novel fused indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2006-05-25 US disclosed
EP-1479670-A1 NOVEL FUSED RING INDAZOLE COMPOUNDS Eisai Co., Ltd. (JP) 2004-11-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060111419-A1 Novel fused indazole compounds MAP2K3, MAP3K11, MAP2K2 MAPK10 39/4885MAPK8 38/4885MAPK9 42/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.